Streetbeat News

Stock Prices

CSGP

CoStar Group has raised its FY24 adjusted EPS outlook from $0.58 - $0.62 to $0.64 - $0.66, surpassing the estimated $0.62.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:16 pm

MTDR

Matador Resources (NYSE:MTDR) reported Q2 earnings per share (EPS) of $2.05, beating the analyst estimate of $1.76 by 16.48%. The company also reported sales of $847.14 million, surpassing the estimate of $826.41 million. Both EPS and sales showed significant year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:15 pm

BTBT

Bit Digital (NYSE:BTBT) has seen a 14.44% increase in its short percent of float, now at 19.1%. This indicates a bearish sentiment among investors, as it has more short interest compared to its peers. It would take traders 1.52 days to cover their short positions.

Portfolio Pulse from Benzinga Insights

July 23, 2024 | 8:15 pm

RRC

Range Resources (NYSE:RRC) reported Q2 2024 adjusted EPS of $0.46, beating the $0.42 estimate and showing a 53.33% increase from last year. Adjusted sales were $641.292M, surpassing the $602.417M estimate and marking an 8.73% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:13 pm

TSLA

Tesla shares are trading lower following mixed Q2 earnings. The company also said it expects 2024 vehicle volume growth to be lower than 2023.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:13 pm

STX

Seagate Technology Holdings has announced its Q1 2025 adjusted EPS forecast of $1.40 ± $0.20, significantly higher than the estimated $0.75. The company also projects revenue of $2.10 billion ± $150 million, surpassing the estimated $1.877 billion.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:12 pm

VSTM

Verastem Oncology (NASDAQ:VSTM) announced a proposed public offering of common stock, warrants, and pre-funded warrants. The size and terms of the offering have not been disclosed. Guggenheim Securities and Cantor are acting as joint book-running managers.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:12 pm

DGX

Quest Diagnostics (NYSE: DGX) reported Q2 adjusted EPS of $2.35, slightly beating the consensus of $2.34. Sales increased by 2.5% year-over-year to $2.39 billion, in line with expectations. The company revised its fiscal year 2024 revenue guidance upwards and forecasts adjusted EPS of $8.80-$9.00. William Blair rates the stock as Outperform, noting stable performance and potential for modest growth.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 8:12 pm

NUVB

Nuvation Bio Inc. (NYSE:NUVB) announced updates for its ROS1 inhibitor, taletrectinib, including upcoming presentations at ESMO 2024 and WCLC 2024. The U.S. FDA has granted Orphan Drug Designation to taletrectinib for treating multiple NSCLC indications.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:11 pm

VICR

Vicor (NASDAQ:VICR) reported Q2 2024 GAAP EPS of $(0.03), missing the $0.05 estimate by 160%. Sales were $85.854M, beating the $81.767M estimate by 5%. EPS decreased by 107.89% YoY, and sales decreased by 19.57% YoY.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:11 pm